One of the most critical medicines in recent medical history, Lipitor remains the world's best-selling pharmaceutical prescribed to treat elevated LDL ("bad") cholesterol and triglycerides, and to prevent cardiovascular disease. Lipitor is proven to reduce the risk of heart attack, stroke and other cardiovascular events in patients with certain cardiovascular risk factors or with heart disease.
Although Lipitor has been available to doctors and patients for more than a decade, Pfizer continues to advance the science demonstrating Lipitor's clinical and economic value. A recent analysis of a Lipitor study presented at the American College of Cardiology 58th Annual Scientific Sessions demonstrated that Lipitor provided sustained reductions in the risk of multiple cardiovascular events in people ages 65 and older with heart disease. This finding is important considering that, this year, an estimated 785,000 Americans will have a new coronary attack, and about 470,000 will have a recurrent attack, according to the American Heart Association.